Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,239)	$ (21,619)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,589	4,389
Depreciation and amortization	1,231	2,083
Impairment of assets held for sale	223
Amortization of intangible assets		142
Bad debt expense		99
Inventory write-off		747
Gain on extinguishment of debt – PPP loan		(3,612)
Change in fair value of common stock warrant liability	(13,719)	(4,134)
Inducement loss on sale of liability classified warrants		5,197
Loss on restructuring and other charges		321
Loss on sale of property and equipment	37	7
Gain on sale of subsidiary and property	(32)
Loss on disposal of property and equipment	3
Changes in operating assets and liabilities:
Accounts receivable	396	2,534
Inventory		136
Prepaid expenses and other current assets	326	(1,392)
Operating lease right-of-use assets	900	1,011
Other assets/liabilities, net	(1)	247
Accounts payable and accrued expenses	(1,064)	(456)
Other current liabilities		(29)
Deferred revenue	(51)	87
Operating lease liabilities	(898)	(1,082)
Net cash used in operating activities	(18,299)	(15,324)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(37)	(18)
Proceeds from sale of property and equipment	195	23
Proceeds from sale of subsidiary and property, net of selling expenses and cash sold	2,327
Net cash provided by investing activities	2,485	5
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from insurance financing arrangements	1,027	1,028
Principal payments on term note payable and financing arrangements	(699)	(708)
Principal payments on financing leases	(256)	(413)
Net proceeds from the sale of common stock, warrants and pre-funded warrants	7,823	9,884
Proceeds from the sale of warrants		1,002
Proceeds from warrants exercised		6,671
Proceeds from pre-funded warrants exercised	3	8
Net proceeds from the sale of preferred stock and warrants	4,814
Cash paid for tax withholdings related to net share settlement	(181)	(355)
Proceeds from stock options exercised		3
Proceeds from ESPP purchase	2	28
Net cash provided by financing activities	12,533	17,148
Net (decrease) increase in cash and cash equivalents	(3,281)	1,829
Cash and cash equivalents - beginning of period	19,375	25,522
Cash and cash equivalents - end of period	16,094	27,351
Supplemental cash flow information:
Cash paid for interest	56	96
Supplemental schedule of non-cash investing and financing activities:
Fair value of placement agent warrants issued in connection with offerings	417	838
Reclassification of warrant liability to stockholders’ equity upon exercise of warrant		8,964
Conversion of Series A and Series B preferred stock into common stock	16
Allocation of proceeds to warrant liability	9,113	8,629
Deferred and accrued offering costs	98	400
Sale of assets held for sale in exchange for a note receivable	400
Reclassification of lease deposit to short term	$ 210